BEIJING, China, February 3, 2026 — Gan & Lee Pharmaceuticals. (hereinafter referred to as "Gan & Lee"; Stock Code: 603087.SH) announced that the insulin glargine injection (pre-filled pen), developed in collaboration with a local Algerian pharmaceutical company, has received registration approval from the Agence Nationale des Produits Pharmaceutiques (ANPP). This is Gan & Lee's first local insulin glargine filling project in Africa, marking a further breakthrough for the company in its expansion into the African market.

The successful registration approval of the insulin glargine injection (pre-filled pen),further enhances the company's commercialized insulin product portfolio in Algeria. Currently, with the successive approval of three insulin products, Gan & Lee has formed a full-category insulin portfolio of long-acting (insulin glargine) + rapid-acting (insulin aspart) + premixed (insulin aspart 30) in the region. This portfolio covers the needs of type 2 diabetes mellitus (T2DM) patients throughout the entire journey of disease management, from early-stage treatment to late-stage therapy. It provides local clinicians with more flexible options for individualized blood glucose management and carries significant clinical value for raising local diabetes treatment rates and reducing the risk of complications.

Behind the continuous improvement of the product layout is the strong support of Gan & Lee's dual strategy: "Localized Production + International Quality Standards." Through deep cooperation with local Algerian enterprises, the company has optimized production costs by leveraging the local supply chain and strictly adhering to international pharmaceutical standards. This has successfully built a "high-quality and cost-competitive" insulin supply system, fundamentally addressing local patients' treatment access challenges. In the future, Gan & Lee will continue to uphold its mission of "Delivering high-quality medicines and services to improve lives worldwide" and further deepen strategic synergy with African partners, contribute Chinese wisdom and expertise to advancing the development of a China-Africa health community.

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee's competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.